AXIS - A suitable case for treatment
Author Information
Author(s): R. Gray, R. James, J. Mossman, S. Stenning
Primary Institution: UK Coordinating Committee on Cancer Research (UKCCCR)
Hypothesis
Can adjuvant therapy improve survival rates in colorectal cancer patients?
Conclusion
The AXIS trial aims to provide clearer evidence on the survival benefits of adjuvant therapies for colorectal cancer.
Supporting Evidence
- Less than 1% of colorectal cancer cases are entered into randomized clinical trials.
- Five of 11 trials of perioperative radiotherapy reported significant reductions in local recurrence.
- Adjuvant systemic chemotherapy may reduce mortality by about 10 to 15%.
Takeaway
Doctors are trying to find out if certain treatments can help people with colon cancer live longer. They need to study a lot of patients to be sure.
Methodology
The AXIS trial is designed to be simple for clinicians to participate in, allowing for flexible treatment schedules and minimal extra work.
Potential Biases
There may be biases in clinician judgment regarding treatment eligibility.
Limitations
Previous trials have not included enough patients to detect moderate improvements in survival reliably.
Participant Demographics
Patients with colorectal cancer, including various stages of the disease.
Statistical Information
P-Value
p<0.06
Statistical Significance
p<0.06
Want to read the original?
Access the complete publication on the publisher's website